Summit Therapeutics Inc. (SMMT) Stock Analysis
Range Bound setup
Healthcare · Biotechnology
Sell if holding. Engine safety override at $17.06: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 4.9/10 and A.R:R 1.8:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 26%; Below-average business quality.
Summit Therapeutics is a clinical-stage oncology biopharmaceutical company developing ivonescimab, a PD-1/VEGF-A bispecific antibody in-licensed from Akeso. A BLA was filed Q4 2025 for ivonescimab in EGFR-mutated NSCLC with a PDUFA date of November 14, 2026. Rights cover the US,... Read more
Sell if holding. Engine safety override at $17.06: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 4.9/10 and A.R:R 1.8:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 26%; Below-average business quality. Chart setup: RSI 57 mid-range, Bollinger mid-band. Score 4.9/10, moderate confidence.
Passes 7/9 gates (positive momentum, favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, earnings proximity no date, semi cycle peak clear). Suitability: moderate.
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHProductivonescimab10-K Item 1A: 'We depend heavily on the success of ivonescimab'
- HIGHSupplierAkeso10-K Item 1A: 'We depend on our relationship with, and the intellectual property licensed from Akeso'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
4 floor-breakers·1 ceiling hit
Volatile — 8.5% daily ATR makes tight stops impractical. Position-size conservatively.static
Quality below the gate floor. Component breakdown shows what dragged the score down.static
No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $17.06: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 4.9/10 and A.R:R 1.8:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 26%; Below-average business quality. Chart setup: RSI 57 mid-range, Bollinger mid-band. Prior stop was $19.96. Score 4.9/10, moderate confidence.
Take-profit target: $27.13 (+26.4% upside). Prior stop was $19.96. Stop-loss: $19.96.
Concentration risk — Product: ivonescimab; Concentration risk — Supplier: Akeso; Quality below floor (2.0 < 4.0).
Summit Therapeutics Inc. trades at a P/E of N/A (forward -18.2). TrendMatrix value score: 9.0/10. Verdict: Sell.
23 analysts cover SMMT with a consensus score of 3.9/5. Average price target: $31.
What does Summit Therapeutics Inc. do?Summit Therapeutics is a clinical-stage oncology biopharmaceutical company developing ivonescimab, a PD-1/VEGF-A...
Summit Therapeutics is a clinical-stage oncology biopharmaceutical company developing ivonescimab, a PD-1/VEGF-A bispecific antibody in-licensed from Akeso. A BLA was filed Q4 2025 for ivonescimab in EGFR-mutated NSCLC with a PDUFA date of November 14, 2026. Rights cover the US, Canada, EU, Japan, and expanded territories.